Oral nifedipine versus intravenous labetalol for hypertensive emergencies during pregnancy: a systematic review and meta-analysis

References

• Buchbinder A, Sibai BM, Caritis S, et al. Adverse perinatal outcomes are signifificantly higher in severe gestational hypertension than in mild preeclampsia. Am J Obstet Gynecol. 2002;186(1):66–71. doi: 10.1067/mob.2002.120080.
   PubMed Web of Science ®Google Scholar
• Gestational hypertension and preeclampsia: ACOG practice bulletin summary, number 222. Obstet Gynecol. 2020;135(6):1492–1495.
   PubMed Web of Science ®Google Scholar
• Bolte AC, van Geijn HP, Dekker GA. Pharmacological treatment of severe hypertension in pregnancy and the role of serotonin2-receptor blockers. Eur J Obstet Gynecol Reprod Biol. 2001;95(1):22–36. doi: 10.1016/S0301-2115(00)00368-7.
   PubMed Web of Science ®Google Scholar
• Magee LA, Helewa M, Rey E, et al. Hypertension guideline C, strategic training initiative in research in the reproductive health sciences S. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can. 2008;30(3):S1–S2. doi: 10.1016/S1701-2163(16)32776-1.
   PubMedGoogle Scholar
• Duley L, Meher S, Jones L. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev. 2013;7:CD001449.
   PubMed Web of Science ®Google Scholar
• Benowitz NL. Antihypertensive agents. In: Katzung BG, Masters SB, Trevor AJ, editors, Basic and clinical pharmacology, 12th ed. New York: Tata-McGraw Hill; 2012. pp. 169–191.
   Google Scholar
• Lindow SW, Davies N, Davey DA, et al. The effect of sublingual nifedipine on uteroplacental blood flow in hypertensive pregnancy. Br J Obstet Gynaecol. 1988;95(12):1276–1281. doi: 10.1111/j.1471-0528.1988.tb06818.x.
   PubMedGoogle Scholar
• Pirhonen JP, Erkkola RM, Ekblad UU. Uterine and fetal flow velocity waveforms in hypertensive pregnancy: the effect of single dose nifedipine. Obstet Gynecol. 1990;76:36–41.
   Web of Science ®Google Scholar
• Moretti MM, Fairlie FM, Akl S, et al. The effect of nifedipine therapy on fetal placental Doppler waveforms in preeclampsia remote from term. Am J Obstet Gynecol. 1990;163(6 Pt 1):1844–1848. doi: 10.1016/0002-9378(90)90762-v.
   PubMed Web of Science ®Google Scholar
• Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13. doi: 10.1186/1471-2288-5-13.
   PubMedGoogle Scholar
• Vermillion ST, Scardo JA, Newman RB, et al. A randomized, double blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy. Am J Obstet Gynecol. 1999;181(4):858–861. doi: 10.1016/s0002-9378(99)70314-5.
   PubMed Web of Science ®Google Scholar
• Shekhar S, Sharma C, Thakur S, et al. Oral nifedipine or intravenous labetalol for hypertensive emergency in pregnancy: a randomized controlled trial. Obstet Gynecol. 2013;122(5):1057–1063. doi: 10.1097/AOG.0b013e3182a9ea68.
   PubMed Web of Science ®Google Scholar
• Raheem I, Saaid R, Omar S, et al. Oral nifedipine versus intravenous labetalol for acute blood pressure control in hypertensive emergencies of pregnancy: a randomised trial. BJOG. 2012;119(1):78–85. doi: 10.1111/j.1471-0528.2011.03151.x.
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Khan S, Jain U, et al. A comparative evaluation of intravenous labetalol versus oral nifedipine for control of severe pregnancy-induced hypertension with low-dose regimen. Int J Med Sci Public Health. 2016;5(6):178. doi: 10.5455/ijmsph.2016.16102015178.
   Google Scholar
• Dhali B, Bhattacharya S, Ganguly RP, et al. A randomized trial of intravenous labetalol & oral nifedipine in severe pregnancy induced hypertension. Int J Reprod Contracept Obstet Gynecol. 2012;1:42–46. doi: 10.5455/2320-1770.ijrcog001912.
   Google Scholar
• Thalamati S, Bandaru S, Bhumireddy D. Assessment of safety and efficacy of oral nifedipine and intravenous labetalol in management of increased blood pressure in severe preeclampsia. Int J Reprod Contracept Obstet Gynecol. 2018;7(7):2645–2649. doi: 10.18203/2320-1770.ijrcog20182465.
   Google Scholar
• Dhananjaya BS, Jamuna R. Oral nifedipine versus intravenous labetalol in hypertensive emergencies of pregnancy: a randomised trial. Res J Pharm Biol Chem Sci. 2015;6:1673–1681.
   Google Scholar
• Das S, Biswas S, Das P, et al. Comparative study of intravenous labetalol and oral nifedipine for control of blood pressure in severe preeclampsia[J]. J Dent Med Sci. 2015;14:22–27.
   Google Scholar
• Shi DD, Yang FZ, Zhou L, et al. Oral nifedipine vs. intravenous labetalol for treatment of pregnancy-induced severe pre- eclampsia. J Clin Pharm Ther. 2016;41(6):657–661. doi: 10.1111/jcpt.12439.
   PubMed Web of Science ®Google Scholar
• Zulfeen M, Tatapudi R, Sowjanya R. IV labetalol and oral nifedipine in acute control of severe hypertension in pregnancy–a randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2019;236:46–52. doi: 10.1016/j.ejogrb.2019.01.022.
   PubMed Web of Science ®Google Scholar
• Sharma M, Thakur S, Singh K, et al. Comparative maternal outcomes of oral nifedipine and intravenous labetalol for severe hypertension during pregnancy: an open label randomized controlled trial. Int J Reprod Contracept Obstet Gynecol. 2020;9(7):2847–2851. doi: 10.18203/2320-1770.ijrcog20202720.
   Google Scholar
• Wasim T, Agha S, Saeed K, et al. Oral nifidepine versus IV labetalol in severe preeclampsia: a randomized control trial. Pak J Med Sci. 2020;36(6):1147–1152. doi: 10.12669/pjms.36.6.2591.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions (version 5.1.0). The Cochrane collaboration. 2011; [cited 2011 Mar 12]. Available from: http://www.cochrane-handbook.org.
   Google Scholar
• Webster K, Fishburn S, Maresh M. et al. Diagnosis and management of hypertension in pregnancy: summary of updated NICE guidance. BMJ. 2019;366:l5119. doi: 10.1136/bmj.l5119.
   PubMed Web of Science ®Google Scholar
• Magee LA, Cham C, Waterman EJ, et al. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ. 2003;327(7421):955–960.
   PubMed Web of Science ®Google Scholar
• Firoz T, Magee LA, MacDonell K., et al. Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. BJOG. 2014;121(10):1210–1218; discussion 1220. Epub 2014 May 16. doi: 10.1111/1471-0528.12737.
   PubMed Web of Science ®Google Scholar
• Shekhar S, Gupta N, Kirubakaran R, et al. Oral nifedipine versus intravenous labetalol for severe hypertension during pregnancy: a systematic review and meta-analysis. BJOG. 2016;123(1):40–47. doi: 10.1111/1471-0528.13463.
   PubMed Web of Science ®Google Scholar
• Barton J, Hiett A, Conover W. The use of nifedipine during the postpartum period in patients with severe preeclampsia. Am J Obstet Gynecol. 1990;162(3):788–792. doi: 10.1016/0002-9378(90)91011-z.
   PubMed Web of Science ®Google Scholar
• Magee LA, Brown MA, Hall DR, et al. The 2021 international society for the study of hypertension in pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2022;27:148–169. Epub 2021 Oct 9. doi: 10.1016/j.preghy.2021.09.008.
   PubMed Web of Science ®Google Scholar
• Magee LA, Smith GN, Bloch C, et al. Guideline no. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management. J Obstet Gynaecol Can. 2022;44(5):547–571.e1. doi: 10.1016/j.jogc.2022.03.002.
   PubMed Web of Science ®Google Scholar
• Chari R, Wilson RD. SOGC’s updated hypertension in pregnancy guideline 2022. J Obstet Gynaecol Can. 2022;44(5):459–460. doi: 10.1016/j.jogc.2022.02.010.
   PubMed Web of Science ®Google Scholar